IQVIA Oncology Dynamics (Mexico)

Field Names
Records
Coordinating Country
Mexico

[IQVIA Oncology Dynamics (Mexico) is part of the IQVIA Global Oncology portfolio]

Region

All regions of Mexico

(This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio. The full portfolio is a global database comprising patient records spanning ten (10) countries:
- China
- France
- Germany
- Italy
- Japan
- Mexico
- Saudi Arabia
- South Korea
- Spain
- UK

Note: While this database is not a statistical sample of the Mexican population, there is a statistical panel designed using a universe study.)

Brief Database Description

IQVIA Oncology Dynamics (Mexico), part of the IQVIA Global Oncology portfolio, provides a  perspective of 14 cancer drug treatment facilitating critical research in areas such as product adoption, dosing, market sizing and off-label use.  

This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio.  This database is not a statistical sample of Mexican population; it is a descriptive cross-sectional database.  The full portfolio is a global database comprising patient records spanning ten (10) countries: China, France, Germany, Italy, Japan, Mexico, Saudi Arabia, South Korea, Spain, and the UK.  The global database has >200,000 patient histories available per year, collected from 2,400 physician. There are approximately 7,000 patients from Mexico expected annually, though the actual database size for Mexico may differ from this projection.

&Nbsp;
IQVIA Oncology Dynamics is a market research tool that has been designed to monitor various cancer treatments and therapies. It segments patients by indication, stage, and line of therapy to provide an understanding of patient pathways, prescribers, products, prescribing initiation and treatment practice patterns.

Potential uses of this database include help with:
(1) Determining patient segmentation and targeting based on actual clinical practice;
(2) Sizing the market accurately to assess brand potential;
(3) Monitoring brand performance, new product uptake and therapy adoption globally;
(4) Evaluating treatment flows from diagnosis to current therapy; and
(5) Benchmarking against competitor performance.

Database Type
Cross-sectional Population Data
- Population Surveys - general (all diseases/or all drugs)

[Data in Mexico as well as other countries - Europe, Canada, China, Japan, Saudi Arabia and South Korea, are collected via a survey methodology in which physicians complete data collection forms for a number of patients per quarter. Based on their workload, physicians are asked to provide case histories from medical records and EMRs for the first "x cap" of patients seen within a specified reporting period (i.e., 15-20 patient cap depending on specialty and site to achieve a sample target by country). The reporting period is specific to country and specialty.]

Database Source
EHR/EMR

Survey Data (other countries)

[Data in Mexico are collected via a survey methodology in which physicians complete data collection forms for a number of patients per quarter. Based on their workload, physicians are asked to provide case histories from medical records and EMRs for the first "x cap" of patients seen within a specified reporting period (i.e., 15-20 patient cap depending on specialty and site to achieve a sample target by country). The reporting period is specific to country and specialty.]

Frequency of Data Collection
Quarterly
Frequency of Data Update
Quarterly

(Approximately 35 days after the end of a quarter)

Years Covered
2018 - Present

(Q1 2018 - Present)

Population Type
Outpatient/Non-Institutionalized

Inpatient

Survey covers all 14 cancer types and stages:
ALL;
CML;
CLL;
NHL;
Breast;
NSCLC;
Prostate;
Colorectal;
Bladder;
Kidney;
Multiple Myeloma,
Pancreas;
Ovarian; and
Melanoma.
(Cancer patients being treated in a hospital inpatient or outpatient setting)

Patient Type
Inpatient and Outpatient

Survey covers all 14 cancer types and stages:
ALL;
CML;
CLL;
NHL;
Breast;
NSCLC;
Prostate;
Colorectal;
Bladder;
Kidney;
Multiple Myeloma,
Pancreas;
Ovarian; and
Melanoma.
(Cancer patients being treated in a hospital inpatient or outpatient setting)

Date of Last Update
Ongoing

[The IQVIA Oncology Dynamics (Mexico) database is updated on an ongoing basis;
This profile was developed for the B.R.I.D.G.E. TO DATA site on August 13, 2019.]

Field Names
Records
Database Population Size
<200,000
Active Population Size
<200,000
Annual Change in Population
N/A

[Not applicable, as this is a cross-sectional survey with natural fallout collection. More specifically, annual sample targets for the database are not collected by indication and instead there are selection criteria for physician case reports to remove any bias (i.e., natural fall out).

Physicians are required to report the first consecutive cases during the reporting period. There is a limit to the number of cases that any one physician can report, regardless of indication.]

Sample Weights - Extrapolation Factors
No

The sample is not weighted in any way. It is meant to give a representative view of the treated prevalent cancer population.

Final Population Size
N/A

(Not applicable, as this database collects data on a quarterly basis)

Field Names
Records
Age of Patients at Data Collection
Yes

(Collected in 5-year brackets)

Approximate Percentage of Participants <18 years and those >65 years

Patients in the database are considered representative of the overall patient population

Gender Data
Yes
Percentage of Males/Females

Patients in the database are considered representative of the overall patient population

Ethnicity / Race Data
No
Geographic Location

All areas of Mexico

Date of Birth Recorded
No
Death Recorded
No

Patients that are reported in the database are currently actively treated, i.e., are alive when reported

Availability of death certificate / autopsy information
N/A

(Not applicable)

Other Demographic Data
No
Field Names
Records
Physician ID
No

All physicians have a unique ID number; however, this information is not available in the database.

Physician Specialty
Yes
Pharmacy ID
N/A

(Not applicable, as no pharmacy data are collected)

Field Names
Records
Diagnosis Data
Yes

Data collection covers all aspects of the patient’s chemotherapy treatment including:
- Cancer diagnosis;
- Histology;
- Assignment therapy;
- Date & time of tests;
- Surgery;
- Platinum status (sensitive or refractory);
- Date & time of therapy;
- Details of the therapy administered; and
- Full demographics that include stage of disease at diagnosis and at relapse. Regular reporting by a panel of physicians in Mexico provides stability in the data.

Drug-treated patients are reported in the database:
1. Date of diagnosis and stage at diagnosis are captured. Therapy type at diagnosis is not necessarily captured unless the patient is newly diagnosed.
2. Patient's current treatment and one historic/previous treatment are captured. The dates of each reported therapy are also captured.
3. Full patient demographics are always captured.

Diagnoses Coded
ICD-10
Diagnoses: Date Parameters
2018 - Present

(Q1 2018 - Present)

Diagnoses: Maximum Number of Codes Allowed
Varies
Physical Examination Findings
Yes

Includes:
Biomarkers;
Ecog Performance Status;
Metastatic Status;
Year Of Diagnosis;
Relapse & Progression;
Co-Morbidities;
Smoking Status; and
Stem Cell Transplant.

Birth Defect Data
No
Cancer Data
Yes

Survey covers all 14 cancer types and stages:
ALL;
CML;
CLL;
NHL;
Breast;
NSCLC;
Prostate;
Colorectal;
Bladder;
Kidney;
Multiple Myeloma,
Pancreas;
Ovarian; and
Melanoma.
(Cancer patients being treated in a hospital inpatient or outpatient setting)

Infectious Disease Data
No
Environmental Exposures
No
Behavioral Data Elements
Yes

Data are often collected on smoking status; However, there is no information regarding alcohol consumption.

Field Names
Records
Procedure Data
Yes

This database only captures data on patients undergoing treatment. Drug treatment options include both anticancer drugs and supportive care. Information is also available on treatment practice patterns and other treatment details, including tumor type, stage. Key biomarker test results are collected.

Procedures Coded
ICD-10
Number of Procedures Coded
Unlimited
Procedure Date Parameters
2018 - Present

(Q1 2018 - Present)

Laboratory Information
Yes

Key biomarker test and chromosomal abnormalities results are collected. There is information on imaging or blood count results. A list of available tests by cancer type can be provided upon request.

Data on diagnostic tests results are available, such as:
HER2 status;
KRAS status;
hormone receptor status;
PD-1/PD-L1;
EGFR plus some EGFR subtypes;
ALK BRAF;
BRCA;
CMET;
NRAS;
ROS-1;
Platinum status PSA; and
Gleason Score.

Chromosomal abnormalities in haematological cancers include:
CLL;
MM;
CML; and
AML.

Field Names
Records
Drug Data
Yes

Information is collected on anticancer drugs and some supportive care drugs. Information on biosimilars will be available as they become available on the market, e.g.:
Molecule;
Regimen;
Route of Admin;
Dose Quantity and Frequency;
Cycles Planned vs. Given;
Treatment Funding;
Maintenance Therapy;
Therapy Initiator;
Side Effects; and
Therapy Context.

Drug Date Parameters
2018 - Present

(Q1 2018 - Present)

Drug Regimen & Route
Yes

Information is collected on:
Route of administration;
Number of times administered per day; and
Number of days given per cycle.

Drug Manufacturer
Yes
Drug Dosage
Yes
Drug Days Supply
Yes

Information is collected on:
Duration for completed drugs;
Any ongoing treatments;
Planned durations; and
Number of cycles.

Drug Coding System: Maximum Number
Unlimited

However, this is limited by character length in data entry field.
NOTE: Some regimens have multiple drugs.

Drug Coding System: Primary
ATC
Drug Coding System: Other
N/A

(Not applicable)

Drug Generic Name
Yes

Generic and brand name (where applicable) is requested.

Drug Additional Information
No
Field Names
Records
Biobank Type
N/A
Human Specimen
N/A
Blood Type
N/A
Biomarkers
N/A
Patient ID
N/A
Number of Samples
N/A
Frequency of Sample Collection
N/A
Pre-diagnostic Sample Collection
N/A
Post-treatment Sample Collection
N/A
Method of Sample Collection
N/A
Age at Sample Collection
N/A
Date of Sample Collection
N/A
Reason for Sample Collection
N/A
Method of Sample Storage
N/A
Length of Sample Storage
N/A
Pathology
N/A
DNA Isolation
N/A
RNA Isolation
N/A
Cell Culture
N/A
Genetic Testing
N/A
Access for Research: Specimens
N/A
Access for Research: Genetic Data
N/A
Access for Research: Epidemiologic Data
N/A
Quality Assurance Procedures
N/A
Family History
N/A
Medical History
N/A
Biobank Linkage
N/A
Field Names
Records
Type of Genetic Database
N/A
Source of Genetic Data
N/A
Specimen Genotyped
N/A
Tissue Form
N/A
Genetic Template
N/A
Gene-Drug Response
N/A
Gene-Disease Relationship
N/A
Gene-Health Outcome Relationship
N/A
Gene-Environment Response
N/A
Method of Imputing Genetic Data
N/A
Genetic Variant Identification
N/A
Genetic Data Level
N/A
Genotyping Method
N/A
Method of Genetic Variant Filtering
N/A
Haplotypes
N/A
Haplogroups
N/A
Variable Number of Tandem Repeats (VNTR)
N/A
Single Nucleotide Polymorphisms (SNPs)
N/A
Variant Type
N/A
Variant Class
N/A
Mutation Indicated
N/A
Position
N/A
Amino Acid Change
N/A
Genotype / Polymorphism
N/A
Allele Frequency
N/A
Linkage Disequilibrium (r²)
N/A
Noncarriers Indicated
N/A
Association Statistics
N/A
Genetic Relatedness Pairing
N/A
Data Sharing: Genetic Data
N/A
Access for Research
N/A
Genetic Data Linkage
N/A
Description of Genetic Data Linkage
N/A
Field Names
Records
Cost Data
No
Cost Denomination
N/A

(Not applicable)

Type of Cost Data
N/A

(Not applicable)

Description of Surrogate Link
N/A

(Not applicable)

Field Names
Records
Data Validation Against Original Source
No

However, numerous quality checks are performed on the data collected to ensure accuracy

Access to Medical Records
No
Linkage to Other Databases
No
Brief Description of Linkage Capabilities

N/A

(Not applicable)

Field Names
Records
Database Contact Data

E-Mail: RWDassets@IQVIA.com

Alternate Contact

N/A

(Not applicable)

Source of Database Funding
Private

(IQVIA)

Sponsoring Government Agency
N/A

(Not applicable)

Sponsoring Pharmaceutical Manufacturer

N/A

(Not applicable)

Database Usage Restrictions
Private Access

(This is a subscription database available to the pharmaceutical industry)

Charge for Database Usage
Yes

Pricing depends on client interest / project scope

Data Media Format
Other

(Access through various analytical formats)

Number of Publications Using Database
N/A

(Not applicable; there are no publications as this is a new database)

References of Studies Using/Describing Database

N/A

(Not applicable; there are no publications as this is a new database)

Database Contact
Database Contact Data

E-Mail: RWDassets@IQVIA.com

Alternate Contact

N/A

References of Studies Using/Describing Database

N/A